Blood peptide protein powder with function of reducing blood sugar and application of blood peptide protein powder

Abstract

The invention discloses hemepeptide protein powder with a hypoglycemic function and application thereof.According to the hemepeptide protein powder with the hypoglycemic function, the activity and glucose uptake capacity of the hemepeptide protein powder (BPPP) on myotubular cells of a C2C12 mouse are evaluated through in-vitro experiments, and it is verified that under the condition that survival activity of the myotubular cells of the C2C12 mouse is not affected, the BPPP promotes the glucose uptake activity of the myotubular cells of the C2C12 mouse in a dose-dependent mode. A mouse in-vivo experiment shows that BPPP can reduce the fasting blood glucose value of an alloxan induced hyperglycemia mouse, the blood glucose reduction percentage is remarkably increased, and the area under a glucose tolerance curve is remarkably reduced, so that the blood peptide protein powder disclosed by the invention can recover the glucose regulation capability of a sick mouse. The invention provides a theoretical basis for application of the blood peptide protein powder in prevention and adjuvant therapy of diabetes and development of related functional foods.

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a blood peptide protein powder with blood sugar lowering function and application thereof. Background Art

[0002] Diabetes is a group of metabolic diseases characterized by high blood sugar, caused by defects in insulin secretion or its impaired action. Diabetes can cause many complications, such as various infections, multiple organ dysfunction syndrome, lipid metabolism disorders, and increased risk of stroke. However, patients with diabetes need to take long-term medication to control their condition. In recent years, with the gradual rise of food-derived functional peptides as an auxiliary treatment for chronic diseases, studies have found that hypoglycemic peptides are widely present in animal foods, and these peptides may be used as an auxiliary treatment for diabetes in the future.

[0003] Animal blood is rich in protein and other nutrients. Currently, there are few data reported on blood-derived glucose-lowering peptides, which indicates that blood-derived glucose-lowering peptides may still be in an underdeveloped stage and deserve continued attention. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes the use of a blood peptide protein powder with blood sugar lowering function in the preparation of a product for treating or assisting in the treatment of hyperglycemia.

[0005] The invention also provides a product.

[0006] According to one aspect of the present invention, the use of blood peptide protein powder in preparing products for treating or assisting in the treatment of hyperglycemia is proposed.

[0007] In some embodiments of the present invention, the peptide content in the blood peptide protein powder is 70%-100%.

[0008] In some embodiments of the present invention, the peptide content in the blood peptide protein powder is 70%, 75%, 80%, 85%, 90%, 95%...100%.

[0009] In some embodiments of the present invention, in the blood peptide protein powder, peptides with a relative molecular mass of less than 10 kDa account for 95%-99.99% of the total peptides.

[0010] In some embodiments of the present invention, in the blood peptide protein powder, the peptides with a relative molecular mass of less than 10 kDa account for 95%, 96%, 97%, 98%, 99%, 99.98%, or 99.99% of the total peptides.

[0011] In some embodiments of the present invention, in the blood peptide protein powder, peptides with a relative molecular mass of less than 1000 Da account for 75%-85% of the total peptides.

[0012] In some embodiments of the present invention, in the blood peptide protein powder, the peptides with a relative molecular mass of less than 1000 Da account for 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%...85% of the total peptides.

[0013] In some embodiments of the present invention, the protein content of the blood peptide protein powder is 85%-96%.

[0014] In some embodiments of the present invention, the amino acids in the blood peptide protein powder include aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine, arginine and tryptophan.

[0015] In some embodiments of the present invention, the mass ratio of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine, arginine and tryptophan is (10-12): (3-5): (4-6): (10-12): (2-4): (4-6): (7-9): (6-8): (0.5-2): (0.5-2): (11-13): (2-4): (5:7): (5-7: (11-13): (3-5): (0.5-2).

[0016] In some embodiments of the present invention, the mass ratio of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine, arginine and tryptophan is 11:4:5:11:3:5:8:7:1:1:12:3:6:6:12:4:1.

[0017] In some embodiments of the present invention, the content of hydrophobic amino acids in the blood peptide protein powder accounts for 30%-40% of the total amino acids.

[0018] In some embodiments of the present invention, the content of hydrophobic amino acids in the blood peptide protein powder accounts for 31.84% of the total amino acids.

[0019] In some embodiments of the present invention, the aliphatic amino acid content in the blood peptide protein powder accounts for 20%-30% of the total amino acids.

[0020] In some embodiments of the present invention, the aliphatic amino acid content in the blood peptide protein powder accounts for 24.85% of the total amino acids.

[0021] In some embodiments of the present invention, the essential amino acid content in the blood peptide protein powder accounts for 40%-50% of the total amino acids.

[0022] In some embodiments of the present invention, the essential amino acid content in the blood peptide protein powder accounts for 40%-45% of the total amino acids.

[0023] In some embodiments of the present invention, the essential amino acid content in the blood peptide protein powder accounts for 43.4% of the total amino acids.

[0024] In some embodiments of the present invention, the product has at least one of the following functions:

[0025] (1) Lowering blood sugar;

[0026] (2) Improve fasting blood sugar;

[0027] (3) restore glucose regulation in diabetic patients;

[0028] (4) Promote glucose uptake by C2C12 myotube cells;

[0029] (5) Prevent and / or treat diabetes.

[0030] In some embodiments of the present invention, the product is at least one of a medicine, a health product and a functional food.

[0031] According to a second aspect of the present invention, a product is provided, comprising blood peptide protein powder.

[0032] In some embodiments of the present invention, the product has at least one of the following functions:

[0033] (1) Lowering blood sugar;

[0034] (2) Improve fasting blood sugar;

[0035] (3) restore glucose regulation in diabetic patients;

[0036] (4) Promote glucose uptake by C2C12 myotube cells;

[0037] (5) Prevent and / or treat diabetes.

[0038] In some embodiments of the present invention, the product is at least one of a medicine, a health product and a functional food.

[0039] In some embodiments of the present invention, the product is a medicine, and the medicine further includes a pharmaceutically acceptable excipient.

[0040] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.

[0041] In some embodiments of the invention, the excipient comprises water.

[0042] In some embodiments of the present invention, the filler comprises at least one of starch and sucrose.

[0043] In some embodiments of the present invention, the binder includes at least one of a cellulose derivative, alginate, gelatin and polyvinyl pyrrolidone.

[0044] In some embodiments of the invention, the humectant comprises glycerin.

[0045] In some embodiments of the present invention, the disintegrant comprises at least one of agar, calcium carbonate and sodium bicarbonate.

[0046] In some embodiments of the invention, the absorption enhancer comprises a quaternary ammonium compound.

[0047] In some embodiments of the invention, the surfactant comprises cetyl alcohol.

[0048] In some embodiments of the present invention, the adsorption carrier includes at least one of kaolin and bentonite.

[0049] In some embodiments of the present invention, the lubricant includes at least one of talc, calcium stearate, magnesium stearate and polyethylene glycol.

[0050] In some embodiments of the present invention, the dosage form of the drug is in the form of solid, semi-solid or liquid, and can be an aqueous solution, non-aqueous solution or suspension.

[0051] In some embodiments of the present invention, the dosage form of the drug is tablets, capsules, soft capsules, granules, pills, oral liquids, dry suspensions, pellets, dry extracts, injections or infusions, transdermal agents, and transdermal microneedles.

[0052] In some embodiments of the present invention, the drug may be administered by any conventional method in the art, including but not limited to injection or oral administration.

[0053] In some embodiments of the present invention, the injection administration can be intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection or subcutaneous injection.

[0054] In some embodiments of the present invention, the mass fraction of the blood peptide protein powder in the product is 0.01% to 100%.

[0055] According to some preferred embodiments of the present invention, the mass fraction of the blood peptide protein powder in the product is 0.05% to 95%.

[0056] According to some preferred embodiments of the present invention, the mass fraction of the blood peptide protein powder in the product is 0.05% to 50%.

[0057] According to some embodiments of the present invention, at least the following beneficial effects are achieved: The present invention evaluates the effect of blood peptide protein powder (BPPP) on the viability and glucose uptake capacity of C2C12 mouse myotube cells through in vitro experiments, and verifies that BPPP promotes the glucose uptake activity of C2C12 myotube cells in a dose-dependent manner without affecting the viability of C2C12 mouse myotube cells. In vivo experiments in mice found that BPPP can reduce the fasting blood glucose value of mice with alloxan-induced hyperglycemia, and the percentage of blood glucose decrease is significantly increased and the area under the glucose tolerance curve is significantly reduced, indicating that the blood peptide protein powder of the present invention can restore the glucose regulation ability of sick mice. The present invention provides a theoretical basis for the use of blood peptide protein powder for the prevention and auxiliary treatment of diabetes and the development of related functional foods. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0059] Figure 1 This is a graph showing the effect of the blood peptide protein powder in Example 2 of the present invention on the viability of C2C12 myotube cells, where, compared with the Control, *p<0.05, n=3;

[0060] Figure 2 This is a graph showing the test results of the effect of the blood peptide protein powder of Example 2 of the present invention on the sugar uptake of C2C12 myoblasts, wherein, compared with the Control, *p<0.05, ***p<0.001, ****p<0.0001, n=3;

[0061] Figure 3 This is a graph showing the test results of the effect of the blood peptide protein powder in Example 2 of the present invention on the body weight of normal animals;

[0062] Figure 4 This is a graph showing the test results of the effect of the blood peptide protein powder in Example 2 of the present invention on blood sugar in normal animals;

[0063] Figure 5The graph is a test result of the blood peptide protein powder in Example 2 of the present invention on the blood sugar lowering effect on alloxan-induced hyperglycemic mice, wherein A is a weight test result graph, B is a fasting blood sugar test result graph, C is a blood sugar test result graph, D is a glucose tolerance test result graph of BPPP on alloxan-induced diabetic model mice, and E is a glucose tolerance curve area under the curve (AUC) test result graph, wherein #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001 compared with the NC group; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared with the DM group, n=10. DETAILED DESCRIPTION

[0064] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0065] The blood peptide protein powder of the present invention was purchased from Guangdong Zhongwang Biotechnology Co., Ltd.

[0066] Example 1 Identification of blood peptide protein powder

[0067] In this example, blood peptide protein powder was identified, and the identification method was as follows:

[0068] 1. Analysis of amino acid types and contents of blood peptide protein powder

[0069] Experimental method: The amino acid determination of blood peptide protein powder was carried out according to the implementation method of GB 5009.124-2016. The determination of amino acids in this standard includes 16 amino acids, including aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine. The determination method includes 7 essential amino acids (threonine, valine, isoleucine, leucine, phenylalanine, lysine, histidine): In addition, the content of tryptophan (one of the essential amino acids) was determined with reference to this standard.

[0070] Table 1

[0071]

[0072]

[0073] Note: Hydrophobic amino acids include Ala, Cys, Val, Met, Ile, Leu, Tyr, Phe and Pro; aliphatic amino acids include Gly, Ala, Val, Ile and Leu; essential amino acids include Lys, Trp, Phe, Met, Thr, Ile, Leu, Val.

[0074] The results of the amino acid composition test of blood peptide protein powder are shown in Table 1. It can be seen from the table that there are 17 total amino acids in blood peptide protein powder, with a total content of 86.73g / 100g. According to GB 5009.124-2016 method, 16 total amino acid species were determined, with a total content of 86.2g / 100g; amino acids were determined according to GB 5009.124-2016 as tryptophan (0.53g / 100g) and cystine was not detected. Among them, Asp, Glu, Ala, Val, Leu and Lys have high contents, and Cys, Met, Trp, and Ile have low contents, which are important sources of essential amino acids. The hydrophobic amino acid and aliphatic amino acid contents in BPPP account for 31.84% and 24.85% of the total amino acid content, and the essential amino acid content accounts for 43.4% of the total amino acid content. The blood peptide protein powder used in this embodiment has a high essential amino acid content, indicating that blood peptide protein powder has a high nutritional value and has a wide range of development and utilization prospects.

[0075] 2. Analysis of protein and peptide content in blood peptide protein powder

[0076] (1) Experimental methods

[0077] The specific method of each test item is shown in Table 2.

[0078] (2) Experimental results

[0079] The results are shown in Table 2. It can be seen from the table that the protein content of the blood peptide protein powder reaches 87.7%, and the content after degradation into peptides reaches 73.5%, among which the peptides with a molecular weight less than 10kDa reach 99.98%, and the peptides with a molecular weight less than 1000Da account for about 80%.

[0080] Table 2 Analysis of protein and peptide content in blood peptide protein powder

[0081]

[0082] Example 2 Application of blood peptide protein powder in developing drugs for treating diabetes

[0083] This example verifies the hypoglycemic effect of the blood peptide protein powder by studying its effect on C2C12 myoblasts and on alloxan-induced hyperglycemic mice. The specific verification method is as follows:

[0084] 1. Effect of blood peptide protein powder on C2C12 myoblasts

[0085] (1) Effect of blood peptide protein powder on the viability of C2C12 myotube cells

[0086] Experimental methods:

[0087] After 4-6 days of differentiation of C2C12 myoblasts, the original culture medium was removed and DMEM high-glucose culture medium was added. The DMEM high-glucose culture medium was configured with drugs of corresponding concentrations (the groups were set as normal group and drug group (the final concentrations of BPPP in the drug group were 50, 100, 200, and 400 μg / mL, respectively)) and reacted for 8 hours. After 8 hours, the culture medium in the well was aspirated, and the 5 mg / mL MTT solution was diluted to 0.5 mg / mL using the basal culture medium under light-proof conditions. 100 μL of the diluted MTT solution was added to each well and placed in an incubator at 37°C and 5% CO 2 , and incubate for 4 hours. After incubation, aspirate the MTT solution, add 150 μL of molecular-grade DMSO solution to each well, place in a microplate constant temperature oscillator, and incubate for 10 minutes in the dark at a temperature of 37°C and an oscillation speed of 340 r / min. After incubation, use an ELISA reader to measure the OD value of each well at a wavelength of 490 nm, and repeat three times.

[0088] The experimental results are as follows Figure 1 As shown in the figure, it can be seen that after the cells were treated with 4 different concentrations of BPPP (50, 100, 200, 400 μg / mL) for 8 hours, BPPP had no significant effect on the survival rate of myotube cells compared with the control group.

[0089] (2) Effect of blood peptide protein powder on the glucose uptake capacity of C2C12 myoblasts

[0090] Experimental methods: The 2-NBDG method was used to detect the effect of BPPP on the glucose uptake capacity of C2C12 myoblasts. C2C12 mouse myoblasts were seeded in black 96-well plates and incubated in 5% CO 2 , cultured in a 37°C constant temperature incubator until the cell confluence reached 100%, replaced the differentiation medium (DMEM+2% HS+1% PS), and changed the cell medium every 24 hours to ensure nutrition. Differentiate for 4-6 days. When the cells differentiated into mature myotubes, the original medium was aspirated, and the medium prepared with DMEM high-glucose basal medium and corresponding concentrations of drugs (the set group was Control, positive drug: metformin (final concentration of 2mM), drug group (final concentration of 50, 100, 200, 400μg / mL)) was added to the well plate and reacted for 8 hours. After 8 hours, the medium was aspirated, and 50μL of 2-NBDG solution prepared with DMEM sugar-free medium at a concentration of 100μM was added to each well, reacted for 30min, and the fluorescence absorption was measured at 475 / 550nm.

[0091] The experimental results are as follows Figure 2 As shown in the figure, it can be seen that after the cells were treated with BPPP at a certain concentration (50, 100, 200, 400 μg / mL) for 8 hours, the 2-NBDG experimental results showed that compared with the normal group, the 50 μg / mL concentration had no obvious effect on the glucose uptake of C2C12 myotube cells, while 100, 200, and 400 μg / mL were all able to promote the glucose uptake of C2C12 myotube cells, and the effect was dose-dependent.

[0092] 2. Study on the effect of blood peptide protein powder on alloxan-induced hyperglycemia in mice

[0093] (1) Effect of blood peptide protein powder on blood sugar in normal animals

[0094] Experimental method: Refer to the "Test Method for Maintaining Healthy Blood Sugar Levels" in the "Health Food Function Test and Evaluation Method" (2023 Edition) to test the ability of blood peptide protein powder to maintain healthy blood sugar levels.

[0095] Experimental animals: SPF-grade healthy adult C57BL male mice (26±2g) were purchased. After acclimation for 5 days, the animals were fasted but not watered for 5 hours, and blood was collected from the tip of the tail to measure fasting blood glucose, which was used as the basal blood glucose value of this batch of animals (see Table 3).

[0096] Dose grouping and test sample administration time: The blood peptide protein powder test sample administration concentration, assuming that the adult body weight is 60kg, takes 5g of blood peptide protein powder (BPPP-H) per day, and the highest dose group is about 10 times the recommended dose for the human body, that is, BPPP-H 850mg / kg·BW. The test group was continuously gavaged for 30 days, and the other normal group (NC) was given ultrapure water as a solvent.

[0097] Table 3 Animal body weight and basal blood glucose level before the test

[0098]

[0099]

[0100] Refer to the method for determining the blood sugar lowering test indicators of normal animals in the "Methods for Testing and Evaluation of Health Food Functions": There was no statistically significant difference between the fasting blood sugar of the high-dose test sample group and the control group (p>0.05), and it was determined that there was no effect on the blood sugar of normal animals.

[0101] The weight and basal blood glucose levels of the mice in this experiment were statistically analyzed. Figure 3-4 As shown, the effect of BPPP-H test concentration on the body weight of mice ( Figure 3 ), fasting blood glucose ( Figure 4) had no statistical significance (p>0.05), therefore, it was determined that blood peptide protein powder had no effect on blood sugar in normal animals.

[0102] (2) Hypoglycemic effect of blood peptide protein powder on alloxan-induced hyperglycemic mice

[0103] Experimental methods:

[0104] 1) Establishment of hyperglycemia model of islet injury

[0105] Healthy adult SPF grade C57BJ male mice (26±2g) were adapted for 5 days. The animals were fasted for 5 hours but not water, and fasting blood glucose was measured as the basal blood glucose value of the batch of animals (as shown in Table 4). Subsequently, the animals were fasted for 24 hours (free drinking water), and alloxan 150mg / kg (freshly prepared before use) was injected intraperitoneally to establish the model. After 3 days, the animals were fasted for 5 hours and blood glucose was measured. Blood glucose values ​​≥11.1mmol / L were considered as successful animals with hyperglycemia model. Another normal group (NC) was set up, which was healthy adult SPF grade C57BJ male mice.

[0106] 2) Experimental animal grouping and drug administration

[0107] The hyperglycemia model animals were randomly divided into 1 model group (DM), 1 positive drug group (Metformin: Metformin 212.5mg / kg·BW), and blood peptide protein powder low-dose group (BPPP-L 212.5mg / kg·BW), medium-dose group (BPPP-M 425mg / kg·BW), and high-dose group (BPPP-H 850mg / kg·BW). The drug group was given different concentrations of the test samples, and the normal group and model group were given solvent ultrapure water for 30 consecutive days, and the fasting blood glucose value was measured (fasting was the same as before the experiment).

[0108] 3) Result determination

[0109] Fasting blood glucose index: Under the premise that the model is established, when the fasting blood glucose of the test sample group is compared with the model group, the decrease in fasting blood glucose or the increase in the percentage of blood glucose decrease is statistically significant, and the fasting blood glucose index result of the test sample is determined to be positive.

[0110] Glucose tolerance index: Under the premise of the establishment of the model, the test sample group is compared with the model group. There is a statistically significant decrease in blood sugar (or an increase in the percentage of blood sugar decrease) at any time point of 0.5 or 2 hours after the administration of glucose, or there is a statistically significant decrease in the area under the blood sugar curve at 0, 0.5, and 2 hours. The glucose tolerance index result of the test sample is determined to be positive.

[0111] Table 4 Body weight and basal fasting blood glucose value of blood peptide protein powder before modeling of hyperglycemic mice induced by alloxan

[0112]

[0113] The experimental results are shown in Table 4 and Figure 5 As shown in Table 4, it can be seen that there is no significant difference in the basal blood glucose values ​​of mice in each group.

[0114] from Figure 5 As can be seen from Figure A, in the first week of administration, there was no significant difference in body weight between normal mice (NC) and hyperglycemic diabetic mice (BPPP-L, BPPP-M, BPPP-H, Metformin). As the gavage time prolonged, the body weight of mice in the NC group gradually increased, showing a significant difference from the DM group. No significant difference was found between the different treatment groups of hyperglycemic diabetic mice, but the body weight of mice in the BPPP-L, BPPP-M, BPPP-H, and Metformin groups were all higher than those in the DM group.

[0115] from Figure 5 As can be seen in Figure B, after the hyperglycemia model was established, the fasting blood glucose values ​​of mice in each group were significantly higher than those in the NC group (p<0.0001). In the early stage of intragastric administration, compared with the DM group, the fasting blood glucose of mice in the drug-treated groups (BPPP-L, BPPP-M, BPPP-H and Metformin) did not decrease significantly, indicating that short-term intragastric administration could not significantly improve the fasting blood glucose of mice. After three weeks of intragastric administration, compared with the model group, the fasting blood glucose of the BPPP-M, BPPP-H and Metformin groups was significantly reduced (p<0.05).

[0116] from Figure 5 As can be seen in Figure C, the percentage decrease in fasting blood glucose in the BPPP-M and BPPP-H drug intervention groups was significant (p<0.01).

[0117] The results of BPPP test on glucose tolerance of alloxan-induced diabetic mice are shown in the figure Figure 5 As shown in Figure D, it can be seen from the figure that after oral administration of glucose, the blood glucose level of mice in the NC group reached the highest level at 30 minutes and dropped to normal at 120 minutes. Compared with the NC group, the blood glucose level of the DM group reached the highest level at 30 minutes, but the blood glucose level was still significantly increased within 120 minutes, indicating that the glucose regulation ability of mice was impaired after modeling. The glucose concentration of the drug intervention group reached a peak at 30 minutes and then gradually decreased. Among them, the blood glucose levels of the Metformin, BPPP-M and BPPP-H groups were significantly reduced at 120 minutes (p<0.05), indicating that the medium and high doses of blood peptide protein powder can significantly reduce the blood glucose level of mice.

[0118] The area under the glucose tolerance curve (AUC) is Figure 5As shown in Figure E, it can be seen from the figure that compared with the NC group, the AUC of the DM group was significantly increased (p<0.0001). Compared with the DM group, the AUC of the drug intervention groups Metformin, BPPP-M and BPPP-H were significantly reduced (p<0.05), indicating that the medium and high doses of blood peptide protein powder can significantly restore the glucose regulation ability of diabetic mice.

[0119] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. Application of blood peptide protein powder in the preparation of products for the treatment or auxiliary treatment of hyperglycemia.

2. The use according to claim 1, characterized in that: The peptide content in the blood peptide protein powder is 70%-100%.

3. The use according to claim 1, characterized in that: In the blood peptide protein powder, peptides with a relative molecular mass of less than 10 kDa account for 95%-99.99% of the total peptides.

4. The use according to claim 1, characterized in that: The protein content of the blood peptide protein powder is 85%-96%.

5. The use according to claim 1, characterized in that: The amino acids in the blood peptide protein powder include aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine, arginine and tryptophan; Preferably, the mass ratio of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine, arginine and tryptophan is (10-12):(3-5):(4-6):(10-12):(2-4):(4-6):(7-9):(6-8):(0.5-2):(0.5-2):(11-13):(2-4):(5:7):(5-7:(11-13):(3-5):(0.5-2).

6. The use according to claim 1, characterized in that: The hydrophobic amino acid content in the blood peptide protein powder accounts for 30%-40% of the total amino acids; And / or, the aliphatic amino acid content in the blood peptide protein powder accounts for 20%-30% of the total amino acids; And / or, the essential amino acid content in the blood peptide protein powder accounts for 40%-50% of the total amino acids.

7. The use according to any one of claims 1 to 6, characterized in that: The product has at least one of the following functions: (1) Lowering blood sugar; (2) Improve fasting blood sugar; (3) restore glucose regulation in diabetic patients; (4) Promote glucose uptake by C2C12 myotube cells; (5) Prevent and / or treat diabetes.

8. A product, characterized in that The product includes blood peptide protein powder.

9. The product according to claim 8, characterized in that The product is at least one of a medicine, a health product and a functional food; Preferably, the drug further comprises a pharmaceutically acceptable excipient; More preferably, the pharmaceutically acceptable excipients include at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.

10. The product according to claim 8, characterized in that The mass fraction of the blood peptide protein powder in the product is 0.01% to 100%.

Images